Callisto Outlines Medical and Market Value of Key Anti-Cancer Drug Candidates in Interview with SmallCapInsights.com

CEO Dr. Gary Jacob Discusses New Treatments for Hematological Cancers and Advantages of FDA 'Orphan Drug' Designations


LOS ANGELES, Oct. 12, 2005 (PRIMEZONE) -- SmallcapInsights.com, http://www.SmallcapInsights.com, the online source for exclusive investor information on Smallcap Investing, announced today the availability of an interview with Dr. Gary S. Jacob, CEO and CSO of Callisto Pharmaceuticals, Inc., (AMEX:KAL) (Frankfurt:CA4), a developer of new drug therapies in the fight against hematologic cancers and related diseases.

In the interview, Dr. Jacob discusses two of Callisto's anti-cancer drug treatments currently in development, Annamycin and Atiprimod, being developed as potential treatments for multidrug resistant tumors, lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), relapsed or refractory multiple myeloma, and osteolytic disease. Dr. Jacob said that Callisto's underlying medical mission is designed to help patients with these cancers who have run out of treatment options. "We know the work that we are doing can really help desperately ill patients," he said.

In addition, Dr. Jacob discusses the competitive and financial advantages Callisto will receive in terms of market exclusivity, as well as federal development support, vis-a-vis the two drug treatments' "orphan drug" designations from the FDA.

This streaming audio interview is available free of charge to all interested investors online by visiting: http://www.SmallcapInsights.com.

About Callisto Pharmaceuticals, Inc.

Callisto is a biopharmaceutical company committed to developing innovative anti-cancer drugs to treat blood cancers and related diseases, including acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), relapsed or refractory multiple myeloma, and osteolytic disease. Callisto also has drugs in preclinical development for gastrointestinal inflammation, as well as for protection against the potential bio-warfare agents, staphylococcus and streptococcus. Callisto's two lead anti-cancer products include Annamycin, a novel liposomal drug from the anthracycline family with potentially reduced cardiotoxicity, a patented liposomal formulation, and the potential to circumvent multi-drug resistance in both ALL and AML; and Atiprimod, a small-molecule oral drug with a potential multiplicity of effects, including tumor cell anti-proliferative and anti-angiogenic activities to treat relapsed multiple myeloma (MM). Atiprimod is presently in a Phase I/IIa clinical trial in relapsed or refractory MM patients at four clinical sites in the U.S. In addition to cancer treatments, Callisto is developing a drug pre-clinically for treatment of inflammatory bowel disease (IBD). Callisto also has received a major biodefense partnership grant from the National Institute of Allergy and Infectious Diseases (NIAID) to develop a monoclonal antibody and vaccine against bacterial superantigen toxins. Bacterial superantigens are among the most lethal of toxins that can potentially be used as bioweapons. For investor-specific information about Callisto, including recent news and stock price data, please visit http://www.trilogy-capital.com/tcp/callisto/. For an Investor Fact Sheet about Callisto, please visit http://www.trilogy-capital.com/tcp/callisto/factsheet.html. Callisto is also listed on the Frankfurt Stock Exchange under the ticker symbol CA4. For additional information, visit www.callistopharma.com.

About SmallCapInsights.com

Forward Looking Statements

Statements made on SmallcapInsights.com may contain forward-looking statements made by senior management of the companies presented here that involve risks and uncertainties, such as statements about plans, objectives, expectations, assumptions or future events. These statements involve estimates, assumptions, known and unknown risks, uncertainties and performances, or achievements expressed or implied by the forward-looking statements. Actual future results and trends may differ materially from those made in-or suggested by-statements presented here due to a variety of factors. Consequently, you should not place undue reliance on any forward-looking statements made here. Many of these and other risks and uncertainties are discussed in greater detail in recent filings with the Securities Exchange Commission for the companies that are present by SmallcapInsights.com.

Compensation and Other Disclosures

SmallCapInsights.com is a wholly-owned subsidiary of Trilogy Capital Partners, Inc. Trilogy Capital Partners provides investor relations services to public companies. The companies presented by SmallCapInsights.com are usually clients of Trilogy Capital Partners and compensate Trilogy Capital Partners for these services, including cash compensation and equity securities. In addition, Trilogy Capital Partners and its affiliates may own securities of the presenting companies, and may from time to time purchase and sell securities of these companies in the open market or in private transactions. Callisto pays $12,500 per month through July 2006 and thereafter for so long as Trilogy is retained to provide investor relations services. In connection with its engagement, Trilogy received non-transferable warrants from this company to purchase 1,793,322 shares of common stock for $1.03 per share expiring in July 2008, provided that the warrants are not exercisable to the extent that following exercise Trilogy would beneficially own 5% or more of the outstanding common stock of the company.



            

Contact Data